Core Insights - ArriVent BioPharma, Inc. is presenting two significant poster presentations at the 2026 AACR Annual Meeting, focusing on innovative biopharmaceutical therapeutics for cancer treatment [1] Group 1: Firmonertinib - Firmonertinib is a novel EGFR inhibitor with high-resolution crystal structure data supporting its pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) [2] - The drug has shown early clinical evidence of activity against uncommon mutations, including exon 20 insertions and PACC variants, and is already approved in China for specific NSCLC cases [3][10] - Preclinical studies indicate firmonertinib's unique structural features enhance binding and activity against EGFR mutant proteins, demonstrating strong anti-tumor activity in various models [5][6] Group 2: ARR-002 - ARR-002, also known as AV-P138-ADC, is a dual-target tetravalent antibody drug conjugate (ADC) aimed at treating ovarian and endometrial cancers, characterized by its superior ADC potential [2][4] - The dual-target approach of ARR-002 is designed to overcome challenges faced by single-target ADCs, showing effective binding and enhanced internalization compared to single-target controls [7] - Initial preclinical data suggest ARR-002 has superior anti-tumor activity in ovarian cancer models, indicating its potential as a best-in-disease ADC [5][8] Group 3: Clinical Development - Firmonertinib is currently undergoing a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations and another for patients with EGFR PACC mutations [12] - ARR-002 is positioned for advancement towards clinical evaluation, with its development leveraging the unique characteristics of its dual-target mechanism [2][4] Group 4: Company Overview - ArriVent is dedicated to the identification, development, and commercialization of differentiated medicines to address unmet medical needs in cancer treatment [9] - The company aims to maximize the potential of its lead candidate, firmonertinib, while advancing a pipeline of novel therapeutics, including next-generation ADCs [9]

Core Insights - ArriVent BioPharma, Inc. is advancing its lead candidate firmonertinib towards potential registration for treating non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, addressing a significant unmet medical need [2][3] - The company reported a cash position of $312.8 million as of December 31, 2025, which is expected to fund operations into the third quarter of 2027 [5][8] - The company is also developing an antibody-drug conjugate (ADC) portfolio, with ARR-217 currently in a Phase 1 trial for gastrointestinal cancers [2][4] Recent and Full Year 2025 Highlights - Firmonertinib is being evaluated in pivotal Phase 3 studies for first-line treatment of NSCLC with EGFR exon 20 insertion mutations and PACC mutations, with topline data expected in mid-2026 [5][12] - Positive final data from the Phase 1b FURTHER trial showed firmonertinib's potential in patients with EGFR PACC mutations, demonstrating clinically meaningful progression-free survival and CNS responses [6][12] - The company completed enrollment for the pivotal FURVENT trial in early 2025, which assesses firmonertinib against platinum-based chemotherapy [6][16] Financial Results - For the year ended December 31, 2025, the company reported a net loss of $166.3 million, compared to a net loss of $80.5 million in 2024 [21] - Research and development expenses increased to $153.4 million in 2025 from $79.0 million in 2024, reflecting investments in clinical trials [21] - General and administrative expenses rose to $24.2 million in 2025 from $15.3 million in 2024 [21] Pipeline Developments - The ADC candidate ARR-217 is in an ongoing Phase 1 trial, with plans to expand the pipeline into multiple solid tumor indications [2][4] - The company plans to file an Investigational New Drug (IND) application for a first-in-class ADC program in the first half of 2026 [13] - Completion of Phase 1 dose escalation for ARR-217 is anticipated in the second half of 2026 [13] Upcoming Milestones - Topline data for firmonertinib in the pivotal FURVENT study is projected for mid-2026 [5][12] - The company aims to present preclinical data for its ADC programs at an upcoming conference [13]

Core Viewpoint - SHP2 inhibitors are emerging as a significant target for cancer treatment, with rapid development in the industry, particularly in China, which is becoming a notable player in the global market [1][6][9]. Industry Overview - SHP2, a protein tyrosine phosphatase, plays a crucial role in regulating various cellular functions, including growth, differentiation, and oncogenic transformation [2][6]. - The global market for SHP2 inhibitors is projected to start existing from 2027, reaching approximately $329 million by 2029, and is expected to grow to $4.821 billion by 2033 [1][7][9]. Market Size - The Chinese SHP2 inhibitor market is anticipated to grow to $206 million by 2029 and reach $784 million by 2033 [9][10]. Industry Chain - The SHP2 inhibitor industry chain includes upstream components such as protein reagents, specific antibodies, small molecule building blocks, testing kits, and experimental models; midstream involves drug research and production; downstream consists of large oncology specialty hospitals and comprehensive hospital oncology departments [11][12]. Development Environment - Recent policies in China have been implemented to encourage the pharmaceutical industry, particularly in the development and production of innovative drugs, including cancer therapies, by shortening clinical application and approval times [13][14]. Competitive Landscape - Major companies in the SHP2 inhibitor space include Innovent Biologics, CanSino Biologics, Junshi Biosciences, and others, with significant progress in developing SHP2 inhibitors, although no drugs have yet been approved for commercialization [15][16]. - Notable companies include: - **QinHao Pharmaceutical**: Focused on developing innovative candidates targeting the RAS signaling pathway, with its lead candidate GH21 in Phase II clinical trials [15][16]. - **Nuocheng Jianhua**: Known for its BTK inhibitor, it is also developing a new SHP2 inhibitor, ICP-189, in collaboration with ArriVent Biopharma [16][17]. Future Outlook - The SHP2 inhibitor sector is one of the hottest areas in pharmaceutical research, with significant advancements in the development of allosteric inhibitors and ongoing clinical trials showing promising results [17][18].

Core Insights - ArriVent BioPharma has initiated the global pivotal Phase 3 ALPACCA study for firmonertinib, targeting first-line treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) [1][2] - Firmonertinib is positioned to address a significant unmet medical need in patients with EGFR PACC mutations, who currently have limited treatment options [2][10] - The ALPACCA study aims to evaluate firmonertinib against osimertinib or afatinib, with primary endpoints including overall response rate (ORR) and progression-free survival (PFS) [2][8] Company Overview - ArriVent is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients [3] - The company aims to leverage its expertise in drug development to maximize the potential of firmonertinib and advance its therapeutic pipeline [3] Product Details - Firmonertinib is an oral, mutation-selective EGFR inhibitor effective against both classical and uncommon EGFR mutations, including PACC mutations [4][5] - The drug has previously received FDA Breakthrough Therapy Designation and Orphan Drug Designation for specific NSCLC patient populations [5] Clinical Study Insights - The ALPACCA study is designed to support potential global registration and includes an estimated 42,000 annual NSCLC patients with EGFR PACC mutations globally, with about 6,200 in the US [2][9] - Firmonertinib's pivotal development is based on previous trial data showing a 16-month median PFS and a 68% confirmed ORR [2][8] Market Context - NSCLC accounts for approximately 85% of all lung cancer cases, with EGFR mutations being a common early event in its development [9] - PACC mutations represent about 12% of all EGFR mutations, highlighting a significant area of unmet medical need due to poor treatment outcomes [9][10]

Core Viewpoint - ArriVent BioPharma, Inc. is making significant progress in its clinical programs, particularly with firmonertinib for treating EGFR-mutant non-small cell lung cancer (NSCLC), and has a strong financial position to support ongoing and future developments [1][2][6]. Company Progress - The firmonertinib program is advancing with two global Phase 3 pivotal studies targeting uncommon EGFR mutant NSCLC populations, with the first patient enrollment in the pivotal Phase 3 trial for PACC mutant NSCLC expected in Q4 2025 [2][7]. - Final Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC was presented at the 2025 World Conference on Lung Cancer, demonstrating clinically meaningful progression-free survival and a manageable safety profile [3][6]. - The antibody-drug conjugate (ADC) portfolio is also progressing, with ARR-217, a CDH17-targeted ADC, currently in a Phase 1 trial and having received FDA IND clearance [4][6]. Financial Highlights - As of September 30, 2025, the company reported cash and investments totaling $305.4 million, expected to fund operations into mid-2027 [6][14]. - For the nine months ended September 30, 2025, net cash used in operations was $129.9 million, with research and development expenses amounting to $121.2 million, which includes a $40 million upfront payment for ARR-217 [14][21]. - The net loss for the nine months ended September 30, 2025, was $130.8 million, compared to a net loss of $59.9 million for the same period in 2024 [14][21]. Upcoming Milestones - The company anticipates topline pivotal data from the global Phase 3 trial in exon 20 insertion mutant NSCLC in early 2026 [2][8]. - The enrollment of the first patient in the randomized global pivotal ALPACCA Phase 3 study for first-line firmonertinib monotherapy in EGFR PACC mutant NSCLC is expected in Q4 2025 [7][8]. Corporate Developments - Brent S. Rice has been appointed as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology and pharmaceutical industry [9].

Core Insights - ArriVent BioPharma, Inc. has appointed Brent S. Rice as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology and pharmaceutical industry [1][2] - The company is focused on the commercialization of firmonertinib for EGFR mutant non-small cell lung cancer (NSCLC) and advancing its antibody drug conjugate (ADC) portfolio [2][4] Company Overview - ArriVent is a clinical-stage biopharmaceutical company dedicated to developing and commercializing differentiated medicines for cancer patients [4] - The company aims to leverage its team's drug development expertise to maximize the potential of its lead candidate, firmonertinib, and advance its pipeline of novel therapeutics [4] Leadership Experience - Brent S. Rice previously served as Senior Vice President and global Chief Commercial Officer at Autolus Therapeutics, where he led the transition from clinical stage to commercial organization [2][3] - He has extensive experience in marketing, operations, and reimbursement, and has a strong track record in launching novel therapies and building high-performing organizations [3]

Core Insights - ArriVent BioPharma, Inc. reported strong progress in its clinical pipeline, particularly with firmonertinib, which is advancing towards registration for treating EGFR-mutant NSCLC [2][6][12] - The company has a robust financial position with cash and investments totaling $254.5 million as of June 30, 2025, and an additional $81.1 million raised in a public offering [6][16] Financial Results - For the six months ended June 30, 2025, net cash used in operations was $94.1 million, an increase from $37.7 million in the same period of 2024, primarily due to a one-time payment of $40 million to Lepu Biopharma [16] - Research and development expenses rose to $89.0 million from $38.8 million year-over-year, driven by the collaboration with Lepu Biopharma and increased clinical expenses related to firmonertinib [16] - The net loss for the six months ended June 30, 2025, was $95.8 million, compared to $39.3 million for the same period in 2024 [16][23] Clinical Pipeline Progress - Firmonertinib has shown promising interim Phase 1b data for EGFR PACC mutant NSCLC, with plans to present final data at the World Conference on Lung Cancer in September 2025 [2][7][8] - The first patient has been dosed in the Phase 1 study for ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, marking a significant milestone in the ADC pipeline [4][6] - The global pivotal Phase 3 ALPACCA study for firmonertinib is expected to enroll its first patient in the second half of 2025, with top-line data from the FURVENT Phase 3 study projected for early 2026 [6][9][14] Market Context - Lung cancer remains the leading cause of cancer-related deaths globally, with NSCLC accounting for approximately 85% of cases [15] - Uncommon EGFR mutations, including exon 20 insertions and PACC mutations, represent significant unmet medical needs, as patients with these mutations have limited treatment options [15][17]

Core Insights - ArriVent BioPharma, Inc. announced that enrollment in the FURVENT Phase 3 study of firmonertinib was completed in Q1 2025, with topline data expected in early 2026 [1] - Firmonertinib has received FDA Breakthrough Therapy Designation for treating patients with untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations [4] Group 1: FURVENT Study - FURVENT is a global Phase 3 trial assessing firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations, comparing it to platinum-based chemotherapy [2] - The study enrolled 398 patients globally, including sites in the United States, Europe, Japan, and China [2] - The primary endpoint is progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST 1.1 [2] Group 2: Firmonertinib Overview - Firmonertinib is an oral, mutation-selective EGFR inhibitor effective against both classical and uncommon EGFR mutations, including exon 20 insertion mutations [3] - It was approved in China in March 2021 for first-line advanced NSCLC with specific EGFR mutations [3] - The drug is also being studied in other global Phase 3 trials targeting different EGFR mutations [5] Group 3: Industry Context - Lung cancer is the leading cause of cancer-related deaths globally, with NSCLC accounting for approximately 85% of all cases [6] - Uncommon EGFR mutations, such as exon 20 insertions, represent about 9% of all EGFR mutations and indicate a significant unmet medical need [6] - Patients with NSCLC harboring uncommon EGFR mutations have a notably lower life expectancy with current therapies [6] Group 4: Company Profile - ArriVent is a clinical-stage biopharmaceutical company focused on developing differentiated medicines for cancer treatment [7] - The company aims to leverage its drug development expertise to advance firmonertinib and other novel therapeutics [8]

Core Viewpoint - ArriVent BioPharma, Inc. plans to offer and sell $75 million of its common stock and pre-funded warrants, with a potential additional 15% option for underwriters, to support its drug development and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes $75 million in common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% [1]. - Goldman Sachs, Citigroup, and Guggenheim Securities are the joint book-running managers for the offering [2]. - An automatic shelf registration statement was filed with the SEC on February 3, 2025, which became effective upon filing [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to support activities related to firmonertinib and other pipeline programs, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - ArriVent is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, with a strong emphasis on its lead candidate, firmonertinib [5].

Firmonertinib Clinical Development - Firmonertinib has Breakthrough Therapy Designation in 1L EGFR Exon 20 insertion mutant NSCLC[6] - Topline results in registrational 1L EGFR Exon 20 insertion mutant NSCLC study are expected in 2025[6] - A pivotal trial for 1L EGFR PACC mutant NSCLC is reinforced by positive clinical data[6] - The company is initiating a global pivotal Phase 3 study in 1L NSCLC PACC mutations[12] - In the FURTHER study, the confirmed Overall Response Rate (ORR) for 1L PACC patients was 68.2% at 240 mg QD and 56% at 160 mg QD[38] - Median Progression-Free Survival (mPFS) was 16 months with 240 mg QD and 11.1 months with 160 mg QD in 1L EGFR PACC mutant NSCLC[43] - The CNS Overall Response Rate (ORR) was 53% and the CNS Complete Response (CR) rate was 41% in CNS evaluable patients from the PACC cohort[46] Pipeline Expansion - The company is advancing a next-generation ADC portfolio, with an IND filed this year and others expected starting in 2026[6] - An IND for ARR-002 (tetravalent dual-target ADC) is planned for 2026[68] - A Phase 1 study for ARR-217 (MRG007) in GI Tumors is expected to enroll its first patient in 2H 2025[69] Market Opportunity - Estimated global patients (excluding China) with metastatic uncommon EGFR mutations is approximately 51,000[63]